We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. Insulet Corporation is among the best value stocks.

TheFly reported on March 13 that Truist observed that PODD shares declined after the company disclosed a Voluntary Device Correction for certain Omnipod 5 lots. While competition in the patch pump market could use the announcement as a minor negative, the reported 18 serious adverse events, including hospitalizations and DKA, involved no fatalities and are expected to have a limited financial effect. Insulet confirmed guidance remains unchanged, and related remediation costs will be excluded from non-GAAP results. Truist considers the stock’s decline to be more severe than justified by potential financial or market-share consequences and maintains a Buy rating with a price target on the shares.

Just days before the device correction, on March 11, Insulet Corporation (NASDAQ:PODD) reported encouraging clinical findings from its EVOLUTION 2C study at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The multicenter feasibility trial evaluated the company’s fully closed-loop automated insulin delivery system for type 2 diabetes in 24 adults, aged 16–70, from a diverse cohort.

Using the final algorithm without boluses, participants’ time in range rose to 68%, a 24% gain over standard injection therapy, while time below range remained minimal at 0.14%. No severe hypoglycemia or DKA occurred, demonstrating improved glucose control without safety compromises across varied participant profiles.

Insulet Corporation (NASDAQ:PODD) is a medical device company that designs, manufactures, and sells the Omnipod insulin management system, a tubeless, wearable insulin pump that helps people with diabetes simplify and personalize their insulin delivery.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.